IGC Pharma Inc
For the period ended Mar 31, 2025. Filed Jun 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jun 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IGC PHARMA, INC. | ||
| Date: June 27, 2025 | By: | /s/ Ram Mukunda |
|---|---|---|
| Ram Mukunda | ||
| President and Chief Executive Officer (Principal Executive Officer) | ||
| Date: June 27, 2025 | By: | /s/ Claudia Grimaldi |
| Claudia Grimaldi | ||
| Vice-president & Chief Compliance Officer (Principal Financial Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Date: June 27, 2025 | /s/ Ram Mukunda |
|---|---|
| Ram Mukunda | |
| President, Chief Executive Officer, and Director (Principal Executive Officer) | |
| Date: June 27, 2025 | /s/ Claudia Grimaldi |
| Claudia Grimaldi Vice-president & Chief Compliance Officer, and Director (Principal Financial Officer) | |
| Date: June 27, 2025 | /s/ Rohit Goel |
| Rohit Goel | |
| Principal Accounting Officer | |
| Date: June 27, 2025 | /s/ Richard Prins |
| Richard Prins | |
| Chairman of the Board of Directors | |
| Date: June 27, 2025 | /s/ James Moran |
| James Moran | |
| Director | |
| Date: June 27, 2025 | /s/ Terry L. Lierman |
| Terry L. Lierman | |
| Director |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.